Literature DB >> 23997143

Do bisphosphonates inhibit direct fracture healing?: A laboratory investigation using an animal model.

T Savaridas1, R J Wallace, D M Salter, A H R W Simpson.   

Abstract

Fracture repair occurs by two broad mechanisms: direct healing, and indirect healing with callus formation. The effects of bisphosphonates on fracture repair have been assessed only in models of indirect fracture healing. A rodent model of rigid compression plate fixation of a standardised tibial osteotomy was used. Ten skeletally mature Sprague-Dawley rats received daily subcutaneous injections of 1 µg/kg ibandronate (IBAN) and ten control rats received saline (control). Three weeks later a tibial osteotomy was rigidly fixed with compression plating. Six weeks later the animals were killed. Fracture repair was assessed with mechanical testing, radiographs and histology. The mean stress at failure in a four-point bending test was significantly lower in the IBAN group compared with controls (8.69 Nmm(-2) (sd 7.63) vs 24.65 Nmm(-2) (sd 6.15); p = 0.017). On contact radiographs of the extricated tibiae the mean bone density assessment at the osteotomy site was lower in the IBAN group than in controls (3.7 mmAl (sd 0.75) vs 4.6 mmAl (sd 0.57); p = 0.01). In addition, histological analysis revealed progression to fracture union in the controls but impaired fracture healing in the IBAN group, with predominantly cartilage-like and undifferentiated mesenchymal tissue (p = 0.007). Bisphosphonate treatment in a therapeutic dose, as used for risk reduction in fragility fractures, had an inhibitory effect on direct fracture healing. We propose that bisphosphonate therapy not be commenced until after the fracture has united if the fracture has been rigidly fixed and is undergoing direct osteonal healing.

Entities:  

Keywords:  Bisphosphonate; Bone plates; Fracture healing; Rat; Tibial fracture; Tibial surgery

Mesh:

Substances:

Year:  2013        PMID: 23997143     DOI: 10.1302/0301-620X.95B9.31562

Source DB:  PubMed          Journal:  Bone Joint J        ISSN: 2049-4394            Impact factor:   5.082


  21 in total

1.  Does bisphosphonate-based anti-osteoporosis medication affect osteoporotic spinal fracture healing?

Authors:  K-Y Ha; K-S Park; S-I Kim; Y-H Kim
Journal:  Osteoporos Int       Date:  2015-07-23       Impact factor: 4.507

2.  Long-term pretreatment with alendronate inhibits calvarial defect healing in an osteoporotic rat model.

Authors:  Chenggui Zhang; Junxiong Zhu; Jialin Jia; Zhiyuan Guan; Tiantong Sun; Wang Zhang; Wanqiong Yuan; Hong Wang; Chunli Song
Journal:  J Bone Miner Metab       Date:  2021-06-06       Impact factor: 2.626

Review 3.  How do bisphosphonates affect fracture healing?

Authors:  Stephen L Kates; Cheryl L Ackert-Bicknell
Journal:  Injury       Date:  2016-01       Impact factor: 2.586

Review 4.  [Basic principles of fracture healing].

Authors:  Valentin Rausch; Dominik Seybold; Matthias Königshausen; Manfred Köller; Thomas A Schildhauer; Jan Geßmann
Journal:  Orthopade       Date:  2017-08       Impact factor: 1.087

5.  Bisphosphonates and direct fracture healing: Area to be explored.

Authors:  Tarun Goyal; Lata Goyal
Journal:  J Pharm Bioallied Sci       Date:  2014-10

6.  Effect of ibandronate on bending strength and toughness of rodent cortical bone: Possible implications for fracture prevention.

Authors:  T Savaridas; R J Wallace; S Dawson; A H R W Simpson
Journal:  Bone Joint Res       Date:  2015-06       Impact factor: 5.853

Review 7.  Ordinary and Activated Bone Grafts: Applied Classification and the Main Features.

Authors:  R V Deev; A Y Drobyshev; I Y Bozo; A A Isaev
Journal:  Biomed Res Int       Date:  2015-11-15       Impact factor: 3.411

8.  Effect of parathyroid hormone on healing in osteoporotic fractures via a phospholipase C-independent pathway.

Authors:  Wei-Long Li; Xiao Yu; Zhi-Ping Huang; Qing-Jiang Pang
Journal:  J Int Med Res       Date:  2017-05-23       Impact factor: 1.671

9.  Randomized clinical trial comparing efficacy and safety of brand versus generic alendronate (Bonmax®) for osteoporosis treatment.

Authors:  Aasis Unnanuntana; Atthakorn Jarusriwanna; Panupan Songcharoen
Journal:  PLoS One       Date:  2017-07-05       Impact factor: 3.240

Review 10.  Sclerostin, an emerging therapeutic target for treating osteoporosis and osteoporotic fracture: A general review.

Authors:  Pui Kit Suen; Ling Qin
Journal:  J Orthop Translat       Date:  2015-09-12       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.